



# Webinar on COVID-19 and Estimands

Thursday, 26 November 2020 14:00-17:00

Dear member of DSBS,

On behalf of the DSBS, we would like to invite you for a webinar on COVID-19 and Estimands. Talks will focus on the general issues seen with COVID-19 and how Estimands may be used to address this. Experiences of handling this in practice will be shared as well. In the end there will be an option for asking questions about the challenges you may have encountered with this.

**Program:**

14:00-14:05	Welcome	<i>Mette Krog Josiassen, Lundbeck</i>
14:05-14:50	What we've learned from the impact of COVID-19 to clinical trials and how estimands have helped us	<i>Chrissie Fletcher, GSK</i>
14:50-15:00	Break	
15:00-16:00	Practical experiences:  Addressing the impact of COVID-19 in trials studying treatment of atopic dermatitis: a reactive and a proactive approach  Addressing COVID-19 in recently completed clinical trials  Impact of COVID-19 on trial conduct in large ongoing outcomes trials  Mitigations of impact of COVID-19 by an interim analysis – experience with a biotech perspective	<i>Per Sørensen, LEO Pharma</i>  <i>Bryan Goldman, Novo Nordisk</i>  <i>Sille Esbjerg, Novo Nordisk</i>  <i>Birgitte Biilmann Rønn, Zealand Pharma</i>
16:00-16:10	Break	
16:10-16:50	Panel discussion - Please send questions on the chat. - The panel will discuss the topics presented and questions from the audience	<i>Chair: Randi Grøn, Novo Nordisk</i>  <i>Panelists:</i> <i>Chrissie Fletcher, GSK</i> <i>Per Sørensen, LEO Pharma</i> <i>Bryan Goldman, Novo Nordisk</i> <i>Sille Esbjerg, Novo Nordisk</i> <i>Birgitte Biilmann Rønn, Zealand Pharma</i>
16:50-17:00	Summary of meeting	<i>Mette Krog Josiassen, Lundbeck</i>

Participation is free. To join, please sign up by sending an email to: [commres1351@Lundbeck.com](mailto:commres1351@Lundbeck.com) at 20 November the latest. A few days before the meeting, you will receive a Teams invite for the meeting.

Kind regards, The DSBS Board